期刊
BIOMOLECULES
卷 10, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/biom10030391
关键词
Parkinson's disease; alpha-synuclein; neurodegeneration; therapy; aggregation
资金
- Fondation de France [00066525]
- France Parkinson Grant
- IDEX Emergence Grant [OPE-2018-410]
- MSER fellowship (France)
- France Parkinson Foundation fellowship
- ANR [ANR-17-CE18-0026-01]
- EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking (IMPRiND grant) [116060]
Parkinson's Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated alpha-synuclein (alpha-syn) protein, which has been shown to be able to propagate from cell to cell and throughout different regions in the brain. Due to its central role in the pathology and the lack of a curative treatment for PD, an increasing number of studies have aimed at targeting this protein for therapeutics. Here, we reviewed and discussed the many different approaches that have been studied to inhibit alpha-syn accumulation via direct and indirect targeting. These analyses have led to the generation of multiple clinical trials that are either completed or currently active. These clinical trials and the current preclinical studies must still face obstacles ahead, but give hope of finding a therapy for PD with time.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据